Effects of a Piperidine Ligand on DNA Modification by Antitumor Cisplatin Analogues

Chemical Research in Toxicology

Volumn 16, Issue 11, 2003, Pages 1424-1432

  Kasparkova, Jana ^a   Novakova, Olga ^a   Najajreh, Yousef ^b   Gibson, Dan ^b,d   Perez, Jose Manuel ^c   Brabec, Viktor ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN DERIVATIVE; DNA; HIGH MOBILITY GROUP PROTEIN; LIGAND; NUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE; PIPERIDINE DERIVATIVE; PLATINUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CHEMICAL MODIFICATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DNA ADDUCT; DNA CONFORMATION; DNA CROSS LINKING; DNA MODIFICATION; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; EXCISION REPAIR; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INTRACELLULAR TRANSPORT;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BINDING SITES; CISPLATIN; CROSS-LINKING REAGENTS; DNA; DNA ADDUCTS; DNA REPAIR; FEMALE; HIGH MOBILITY GROUP PROTEINS; HUMANS; LIGANDS; OLIGODEOXYRIBONUCLEOTIDES; OVARIAN NEOPLASMS; PIPERIDINES; PLATINUM COMPOUNDS; SEQUENCE ANALYSIS, DNA; SPAIN; TUMOR CELLS, CULTURED;

EID: 0345283279     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx034128g     Document Type: Article

References (39)

1. Kelland, L. R. (2000) New platinum drugs, The pathway to oral therapy. In Platinum-Based Drugs in Cancer Therapy (Kelland, L. R., and Farrell, N. P., Eds.) pp 299-319, Humana Press Inc., Totowa, NJ.
2. Johnson, N. P., Butour, J.-L., Villani, G., Wimmer, F. L., Defais, M., Pierson, V., and Brabec, V. (1989) Metal antitumor compounds: The mechanism of action of platinum complexes. Prog. Clin. Biochem. Med. 10, 1-24.
3. Brabec, V. (2002) DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. In Progress in Nucleic Acid Research and Molecular Biology (Moldave, K., Ed.) Vol. 71, pp 1-68, Academic Press Inc., San Diego, CA.
4. Khazanov, E., Barenholz, Y., Gibson, D., and Najajreh, Y. (2002) Novel apoptosis-inducing trans-platinum piperidine derivatives: Synthesis and biological characterization. J. Med. Chem. 45, 5196-5204.
5. Najajreh, Y., Perez, J. M., Navarro-Ranninger, C., and Gibson, D. (2002) Novel soluble cationic trans-diamminedichloroplatinum(II) complexes that are active against cisplatin resistant ovarian cancer cell lines. J. Med. Chem. 45, 5189-5195.
6. Kasparkova, J., Marini, V., Najajreh, Y., Gibson, D., and Brabec, V. (2003) DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines. Biochemistry 42, 6321-6332.
7. Zamble, D. B., and Lippard, S. J. (1999) The response of cellular proteins to cisplatin-damaged DNA. In Cisplatin. Chemistry and biochemistry of a leading anticancer drug (Lippert, B., Ed.), pp 73-110, VHCA, WILEY-VCH, Zürich, Weinheim.
8. Kasparkova, J., Delalande, O., Stros, M., Elizondo-Riojas, M. A., Vojtiskova, M., Kozelka, J., and Brabec, V. (2003) Recognition of DNA interstrand cross-link of antitumor cisplatin by HMGB1 protein. Biochemistry 42, 1234-1244.
9. Wei, M., Cohen, S. M., Silverman, A. P., and Lippard, S. J. (2001) Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins. J. Biol. Chem. 276, 38774-38780.
10. Malina, J., Kasparkova, J., Natile, G., and Brabec, V. (2002) Recognition of major DNA adducts of enantiomeric cisplatin analogues by HMG box proteins and nucleotide excision repair of these adducts. Chem. Biol. 9, 629-638.
11. Zamble, D. B., Mu, D., Reardon, J. T., Sancar, A., and Lippard, S. J. (1996) Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 35, 10004-10013.
12. Reardon, J. T., Vaisman, A., Chaney, S. G., and Sancar, A. (1999) Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclobexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res. 59, 3968-3971.
13. Brabec, V., Reedijk, J., and Leng, M. (1992) Sequence-dependent distortions induced in DNA by monofunctional platinum(II) binding. Biochemistry 31, 12397-12402.
14. Brabec, V., and Leng, M. (1993) DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues. Proc. Natl. Acad. Sci. U.S.A. 90, 5345-5349.
15. Stros, M. (2001) Two mutations of basic residues within the N-terminus of HMG-1 B domain with different effects on DNA supercoiling and binding to bent DNA. Biochemistry 40, 4769-4779.
16. Kasparkova, J., Mellish, K. J., Qu, Y., Brabec, V., and Farrell, N. (1996) Site-specific d(GpG) intrastrand cross-links formed by dinuclear platinum complexes. Bending and NMR studies. Biochemistry 35, 16705-16713.
17. Kasparkova, J., Farrell, N., and Brabec, V. (2000) Sequence specificity, conformation, and recognition by HMG1 protein of major DNA interstrand cross-links of antitumor dinuclear platinum complexes. J. Biol. Chem. 275, 15789-15798.
18. 3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts. Biochemistry 42, 792-800.
19. Brabec, V., Sip, M., and Leng, M. (1993) DNA conformational distortion produced by site-specific interstrand cross-link of trans-diamminedichloroplatinum(II). Biochemistry 32, 11676-11681.
20. +. Chem. 35, 179-188.
21. Kasparkova, J., Novakova, O., Vrana, O., Farrell, N., and Brabec, V. (1999) Effect of geometric isomerism in dinuclear platinum antitumor complexes on DNA interstrand cross-linking. Biochemistry 38, 10997-11005.
22. He, Q., Ohndorf, U.-A., and Lippard, S. J. (2000) Intercalating residues determine the mode of HMG1 domains A and B binding to cisplatin-modified DNA. Biochemistry 39, 14426-14435.
23. Missura, M., Buterin, T., Hindges, R., Hubscher, U., Kasparkova, J., Brabec, V., and Naegeli, H. (2001) Double-check probing of DNA bending and unwinding by XPA-RPA: an architectural function in DNA repair. EMBO J. 20, 3554-3564.
24. Kasparkova, J., Zehnulova, J., Farrell, N., and Brabec, V. (2002) DNA interstrand cross-links of the novel antitumor trinuclear platinum complex BBR3464. Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair. J. Biol. Chem. 277, 48076-48086.
25. Kelland, L. R., Mistry, P., Abel, G., Loh, S. Y., O'Neill, C. F., Murrer, B. A., and Harrap, K. R. (1992) Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using 2 pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res. 52, 3857-3864.
26. Fernández-Ruíz, R., Tornero, J. D., González, V. M., and Alonso, C. (1999) Quantification of Pt bound to DNA using total-reflection X-ray fluorescente (TXRF). Analyst 124, 583-585.
27. 2(N,N-dimethylamine) (isopropylamine)] in A2780cisR ovarian tumor cells. Metal-Based Drugs 8, 29-37.
28. Brabec, V. (2000) Chemistry and structural biology of 1,2-interstrand adducts of cisplatin. In Platinum-Based Drugs in Cancer Therapy (Kelland, L. R., and Farrell, N. P., Eds,) pp 37-61, Humana Press Inc., Totowa, NJ.
29. 3 by an iminoether in transplatin makes an antitumor drug from an inactive compound. Mol. Pharmacol. 58, 1525-1535.
30. Brabec, V., Neplechova, K., Kasparkova, J., and Farrell, N. (2000) Steric control of DNA interstrand cross-link sites of trans platinum complexes: specificity can be dictated by planar non-leaving groups. J. Biol. Inorg. Chem. 5, 364-368.
31. Bancroft, D. P., Lepre, C. A., and Lippard, S. J. (1990) Pt-195 NMR kinetic and mechanistic studies of cis-diamminedichloroplatinum and trans-diamminedichloroplatinum(II) binding to DNA. J. Am. Chem. Soc. 112, 6860-6871.
32. 2, a metabolite of an orally active platinum anticancer drug. J. Am. Chem. Soc. 114, 5646-5654.
33. Sancar, A. (1996) DNA excision repair. Annu. Rev. Biochem. 65, 43-81.
34. Reardon, J. T., and Sancar, A. (1998) Molecular mechanism of nucleotide excision repair in mammalian cells. In Advances in DNA Damage and Repair (Dizdaroglu, M., and Karakaya, A., Eds.) pp 377-393, Plenum Publishing Corp., New York.
35. Stehlikova, K., Kostrhunova, H., Kasparkova, J., and Brabec, V. (2002) DNA bending and unwinding due to the major 1,2-GG intrastrand cross-link formed by antitumor cis-diamminedichloroplatinum(II) are flanking-base independent. Nucleic Acids Res. 30, 2894-2898.
36. Malina, J., Hofr, C., Maresca, L., Natile, G., and Brabec, V. (2000) DNA interactions of antitumor cisplatin analogues containing enantiomeric amine ligands. Biophys. J. 78, 2008-2021.
37. Fuertes, M. A., Castilla, J., Alonso, C., and Perez, J. M. (2003) Cisplatin biochemical mechanism of action: From cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr. Med. Chem. 10, 257-266.
38. Kartalou, M., and Essigmann, J. M. (2001) Recognition of cisplatin adducts by cellular proteins. Mutat. Res. 478, 1-21.
39. Kelland, L. R. (2000) Preclinical perspectives on platinum resistance. Drugs 59, 1-8.